



2020/12/11

Company:	CYBERDYNE Inc.
Name of Representative:	Yoshiyuki Sankai, President and CEO
Code:	7779 (Mothers Section of the Tokyo Stock Exchange)
Contact:	Shinji Uga, Director and CFO (Tel. +81-29-869-9981)

【News】 Stroke clinical trial on Medical HAL is complete

CYBERDYNE Inc. [Tsukuba, Ibaraki, CEO: Yoshiyuki Sankai (the “Company”)] announces that a clinical trial with HAL for Medical Use Lower Limb Type Single-Leg Model is complete. The investigator-initiated clinical trial was to investigate the efficacy of improving the physical function of a stroke patient with hemiplegia. The summary of the result of the trials is scheduled to be announced in June 2021.

The trial that began in September 2016 was conducted at 16 different sites, such as the lead-investigator University of Tsukuba Hospital, Ibaraki Prefectural University of Health Sciences Hospital, and Hyogo Rehabilitation Center. The trial was funded by the Japan Agency for Medical Research and Development.

Ref) Registered information on UMIN-CTR

https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000028545